25-008 Part A: Alzheimer’s disease and schizophrenia study
Recruiting Soon
1 Jul 2026
£1,250 - £2,315
London, United Kingdom
A study investigating an experimental new medicine for problems with thinking such as memory and concentration, linked to neurological conditions like Alzheimer’s disease (AD) and schizophrenia.
Join our clinical trial
We’re doing this trial to test an experimental new medicine for treating cognitive decline or impairment in neurological disorders. The study medicine acts at sites in the brain called ‘TrkB receptors’. By acting on those sites, we hope it will help regulate the chemical imbalances in the brain linked to neurological disorders, and so improve patients’ symptoms. We’re conducting this study in healthy volunteers to see if a single dose causes any side effects when taken by mouth, how much of the medicine (and its breakdown products) enters the blood and urine, how long it takes the body to remove it, and whether eating food changes how well the medicine is absorbed into the bloodstream.
Why participate?
If you take part in this trial, you’ll be helping medical research – you could help us develop a potential new treatment for cognitive decline or impairment.
In the UK, about 1 in 6 people have a neurological disorder. Types of neurological disorders include AD, which affects 60 million people worldwide, and schizophrenia, which affects 24 million people worldwide. Neurological disorders affect the brain and include a wide range of symptoms, but people with neurological disorders often have cognitive decline or impairment. People with cognitive decline can experience problems with short term memory, planning, language, and/or attention.
Trial details
Delivery method
You’ll take your dose of trial medicine by mouth, as capsules
Schedule
The study is scheduled to begin in July 2026.
- During the 4 weeks before you start the study, we’ll screen you to see if you’re suitable
- You’ll have 1 or 2 sessions depending on your group. Each session consists in 3 days and 2 nights’ residence on the ward
- You’ll return to the ward about 1 week after we’ve discharged you, for a final check-up. If you do Session 2, you’ll have a follow-up visit about 1 week after each session
The planned admission dates are:
- 17 Aug 2026
- 18 Aug 2026
- 14 Sep 2026
- 15 Sep 2026
- 12 Oct 2026
- 13 Oct 2026
You’ll receive £1,250 if you take part in one session, or at least £2,315 if you complete two sessions.
Inclusion criteria:
You must:
- be a healthy man or woman, aged 18 to 55
- be willing to eat a fatty breakfast containing eggs and dairy
- be willing to use contraception
Exclusion criteria
You must not:
- use regular medication
- smoke more than 2 cigarettes a week or use a vaping device more than twice in a week
- have had a tattoo or piercing in the past 3 months or plan to do so during the study
Are you a match?
Age
18 - 55 years old
Study payment
£1,250 - £2,315
Gender
Male or Female
BMI
BMI 18 - 30.9 kg/m2
Commitment
2 - 4 nights, 2 clinic visits